As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.
14 Analysts have issued a InflaRx N.V. forecast:
14 Analysts have issued a InflaRx N.V. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 0.19 0.19 |
58%
58%
|
|
| Gross Profit | -2.52 -2.52 |
119%
119%
|
|
| EBITDA | -59 -59 |
2%
2%
|
|
| EBIT (Operating Income) EBIT | -59 -59 |
2%
2%
|
|
| Net Profit | -52 -52 |
3%
3%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
| Head office | Netherlands |
| CEO | Niels Riedemann |
| Employees | 74 |
| Founded | 2007 |
| Website | www.inflarx.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


